USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/34472
Title: SARCOPENIA AS A CHALLENGE IN THE USE OF GLP-1 RECEPTOR AGONIST THERAPIES
Authors: Malai, Mirela
Keywords: GLP-1 receptor agonists;sarcopenia;risk factors;strategies for prevention
Issue Date: 2026
Publisher: Centrul Editorial-Poligrafic Medicina
Citation: Malai, Mirela. SARCOPENIA AS A CHALLENGE IN THE USE OF GLP-1 RECEPTOR AGONIST THERAPIES. In: MedEspera 2026, p. 657. ISBN 978-9975-82-486-6.
Abstract: Introduction. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes mellitus and obesity due to their effects on glycemic control and weight reduction. Although weight loss is primarily associated with a reduction in adipose tissue, part of the weight loss also involves a decrease in lean body mass. Sarcopenia represents a potential clinical challenge, particularly in older patients or in individuals with initially reduced muscle mass. Aim of study. The aim of this study was to analyze the impact of GLP-1 receptor agonist therapies on body composition, with a focus on the mechanisms involved in muscle mass loss and on strategies for the prevention of sarcopenia. Methods and materials. Relevant articles published over the past 10 years were analyzed from international databases, including PubMed Central, Elsevier, The Lancet, and Medscape. Randomized clinical trials, meta-analyses, and observational studies evaluating the effects of GLP-1RAs on body weight and body composition were included, along with data regarding therapeutic interventions aimed at preserving muscle mass. Results. Treatment with GLP-1RAs induces weight loss mainly through appetite suppression and delayed gastric emptying. However, prolonged energy deficit and reduced protein intake may promote muscle mass loss. At the molecular level, reduced insulin and IGF-1 levels associated with energy restriction may decrease the activity of the PI3K-Akt-mTOR signaling pathway, thereby reducing muscle protein synthesis. Epidemiologically, muscle mass loss affects approximately 20-40% of patients on intensive GLP-1RA therapy. Key risk factors include: advanced age (>65 years), low baseline protein intake, sedentary lifestyle, and a rapid rate of weight loss (exceeding 1-2 kg per week). In addition, discontinuation of therapy is frequently followed by weight regain, with disproportionate recovery of fat mass compared with muscle mass. To limit muscle mass loss, both pharmacological and non-pharmacological strategies are being investigated. Pharmacological approaches include inhibitors of the myostatin/activin signaling pathway, while non-pharmacological interventions remain essential. Resistance training and adequate protein intake contribute to maintaining muscle protein synthesis and improving body composition. Conclusions. Lean mass reduction during GLP-1RA therapy is primarily driven by energy-restriction-induced downregulation of the PI3K-Akt-mTOR pathway, especially in elderly patients and those with rapid weight loss. Effective prevention strategies must integrate pharmacological innovations, such as myostatin/activin inhibitors, with essential non-pharmacological interventions like resistance training and optimized protein intake to ensure high-quality weight loss.
metadata.dc.relation.ispartof: MedEspera 2026. The 11th International Medical Congress for Students and Young Doctors, 6-8 May 2026
URI: https://medespera.md/documents/abstract-book-4.pdf
https://repository.usmf.md/handle/20.500.12710/34472
ISBN: 978-9975-82-486-6
Appears in Collections:MedEspera 2026

Files in This Item:
File Description SizeFormat 
M-657.pdf467.07 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback